Strategic Analysis of the Global Breast Cancer Therapeutics Pipeline
Strategic Analysis of the Global Breast Cancer Therapeutics Pipeline
RELEASE DATE
03-Jun-2004
03-Jun-2004
REGION
North America
North America
Research Code: A845-01-00-00-00
SKU: HC00979-NA-MR_04855
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
HC00979-NA-MR_04855
Description
This research service includes many aspects of the pipeline analysis for the breast cancer therapeutics market including: drivers, restraints, existing market trends, pipeline trends, challenges, biotech out-licensing trends and strategies, strategic company profiles, financial analysis and awards.
Table of Contents
Overview
- Introduction
- Disclaimer
- Certification
Summary
- Outline Slide
- Summary of Findings
- Summary of Findings by Segment
- Research Scope and Methodology
- Competitive Framework
- Technology Evolution Trajectory
- Potential Threats
Strategic Analysis
- Outline Slide
- Market Segmentation
- Market Drivers
- Market Restraints
- Industry Challenges
- Existing Companies
- Existing Products
Competitive Landscape
- Outline Slide
- Pipeline Therapeutic Trends
- Value of Biotech Out-License Deals
- Average Size of Biotech Out-License Deals
- Average Size of Biotech Out-License Deals by Payment Class
- Average Size of Biotech Out-License Deals by Stage
- U.S. Drug Approval Process
Phase I Pipeline Analysis
- Outline Slide
- Clinical Development Slide
- R1550 (Antisoma)
- Panzem (EntreMed)
- CEA-Cide (Immunomedics)
- Executive Quote (Immunomedics)
- HER-2/neu Vaccine (Corixa)
- BrevaRex (AltaRex)
Phase II Pipeline Analysis A
- Outline Slide
- Clinical Development Slide
- APC8024 (Dendreon)
- Executive Quote (Dendreon)
- Advexin (Introgen)
- Iressa (AstraZeneca)
- Zarnestra (Johnson & Johnson)
- Telcyta (Telik)
- TriAb (Titan Pharmaceuticals)
- INGN 225 (Introgen)
- Xyotax (Cell Therapeutics)
- BMS-275291 (Bristol-Myers Squibb)
- ERA-923 (Wyeth)
Phase II Pipeline Analysis B
- Omnitarg (Genentech)
- CI-1033 (Pfizer)
- CCI-779 (Wyeth)
- LEP/LED (NeoPharm)
- Alimta (Lilly)
- Genasense (Genta)
Phase III Pipeline Analysis A
- Outline Slide
- Clinical Development Slide
- Enhanzyn (Corixa)
- Avastin (Genentech)
- Doxil (Alza)
- Arzoxifene (Eli Lilly)
- GW-572016 (GlaxoSmithKline)
- Atamestane (BioMedicines)
- Tavocept (BioNumerik)
- Evista (Eli Lilly)
- Gemzar (Eli Lilly)
- Herceptin (Genentech)
Phase III Pipeline Analysis B
- Lasofoxifene (Pfizer)
- Navelbine (GlaxoSmithKline)
- Theratope (Biomira)
- Executive Quote (Biomira)
- 109881-Taxoid (Aventis)
- Celebrex (Pfizer)
- Xeloda (Roche)
- Tesmilifene (YM Biosciences)
- Executive Quote (YM Biosciences)
Company Analysis
- Outline Slide
- AltaRex and Alza
- Antisoma and AstraZeneca
- Aventis and BioMedicines
- BioMira and BioNumerik
- Bristol-Myers Squibb and CellTech
- Cell Therapeutics and Corixa
- Dendreon and EntreMed
- Genentech and Genta
- GlaxoSmithKline and Immunomedics
- Introgen Therapeutics and Johnson & Johnson
- Ligand Pharmaceuticals and Eli Lilly
- NeoPharm and Pfizer
- Roche and Telik
- Titan Pharmaceuticals and Wyeth
- YM Biosciences
Decision Support Databases
- Outline Slide
- Breast Cancer Incidence A
- Breast Cancer Incidence B
- Biotechnology Companies A
- Biotechnology Companies B
- Pharmaceutical R&D Expenditure A
- Pharmaceutical R&D Expenditure B
Frost & Sullivan Awards
- Outline Slide
- Introduction to Frost & Sullivan Awards
- Growth Strategy of the Year Award
- Innovative Technology Leadership of the Year Award
- Business Development Strategy Leadership of the Year Award
- Biotechnology Emerging Company of the Year Award
Frost & Sullivan
- Outline Slide
- Healthcare Team
- Our Capabilities
- Key Advantages
- Our Consulting Clients
- Frost & Sullivan Growth Consulting
- Growth Consulting Process
- Growth Consulting Deliverables
- Growth Partnership Services
- Growth Partnership Service Platform
Popular Topics
This research service includes many aspects of the pipeline analysis for the breast cancer therapeutics market including: drivers, restraints, existing market trends, pipeline trends, challenges, biotech out-licensing trends and strategies, strategic company profiles, financial analysis and awards.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | A845-01-00-00-00 |
Is Prebook | No |